![Sarepta Therapeutics Inc Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/srpt.png?tr=w-200)
Sarepta Therapeutics Inc
NASDAQ:SRPT
![Sarepta Therapeutics Inc Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/srpt.png)
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Realty Income Corp
NYSE:O
|
Real Estate
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/srpt.png)
Sarepta Therapeutics Inc
Cash from Operating Activities
Sarepta Therapeutics Inc
Cash from Operating Activities Peer Comparison
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/abbv.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/gild.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/amgn.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/vrtx.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/regn.png)
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
![]() |
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
Cash from Operating Activities
-$533.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-21%
|
![]() |
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$22.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
15%
|
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$8.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
8%
|
![]() |
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
2%
|
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.7B
|
CAGR 3-Years
22%
|
CAGR 5-Years
14%
|
CAGR 10-Years
24%
|
See Also
What is Sarepta Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-533.7m
USD
Based on the financial report for Mar 31, 2024, Sarepta Therapeutics Inc's Cash from Operating Activities amounts to -533.7m USD.
What is Sarepta Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-21%
Over the last year, the Cash from Operating Activities growth was -23%. The average annual Cash from Operating Activities growth rates for Sarepta Therapeutics Inc have been 9% over the past three years , -1% over the past five years , and -21% over the past ten years .